Pipeline
Programs addressing skin, gut and lung
Lead programs address colitis in cancer patients receiving ICI therapy, life-threatening skin wounds in the rare disease SAVI, and preserving lung function in rare and genetic diseases.
ILP100-Oral
Colitis in cancer patients receiving ICI therapy
L. reuteri expressing human CXCL12 1a (emilimogene sigulactibac) for local immunomodulation in the gut. Superior efficacy versus marketed benchmarks in preclinical colitis models.
ILP100-Topical
Difficult-to-treat skin wounds (SAVI) and MDR infections
A first-in-human double-blinded RCT showed a favourable safety profile and significantly 10 days faster skin healing. IND open in the US; Rare Pediatric Disease Designation from the FDA.
ILP101-Inhale
Lung infections in rare diseases (SAVI, cystic fibrosis)
L. reuteri expressing human CXCL17, a mucosal chemokine with anti-inflammatory and bacteria-killing effects, aiming to preserve lung function.
AMR / MDR pipeline
Pan-resistant bacterial infections
Non-disclosed assets addressing the untapped opportunity of eliminating pan-resistant bacterial infections with lactic acid bacteria.
Platform
Competitive advantages
The modality is classified as GTMP and gene therapy by the EMA and FDA respectively, with access to accelerated pathways such as FDA RPDD, RMAT and EMA PRIME.
- Unlocks drugging of > 1700 proteins
- Favourable safety profile(s)
- Manufactured at large scale
- Low COGs and potential for competitive margins
- Logistics and storage at ambient temperature
- Addresses a wide range of diseases in skin and mucosa